NASDAQ:CYCN 6 January 2026

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics shares surged 46% to $2.01 premarket Tuesday after announcing an expanded exclusive collaboration with Medsteer for its CYC-126 depression program. The company aims to start a Phase 2 proof-of-concept study in late 2026, with initial data expected in 2027. Cyclerion flagged “substantial doubt” about its ability to continue as a going concern and said it needs more funding.

6 January 2026

Biotechnology·NASDAQ:CYCN·Stock Market

PCBL Chemical Shares Surge 17% Amid Volume Spike: Experts Weigh In
March 25, 2026, 6:09 AM EDT. PCBL Chemical shares soared over 17% intraday on BSE, hitting ₹274 from ₹233.30. The stock saw a sharp volume spike with over 4 crore shares traded. Despite a 13% drop in March and a 10% year-to-date decline, experts signal potential gains if prices hold above ₹226.50. Analyst Aditya Thukral highlights a strong long-term bullish base, noting prices crossing ₹254.5 suggest strength. He targets ₹300-₹320 in the short term, with ₹330 a key resistance marking a long-term bullish reversal. Choice Broking's Hitesh Tailor mentions the need for confirmation beyond this rally, pointing to mixed signals in weekly and monthly charts. Investors should watch for a decisive breakout above ₹330 to confirm sustained upward momentum.